Bio-Gene Technology Limited (ASX:BGT)
Australia · Delayed Price · Currency is AUD 0.0230
+0.0010 (4.55%)
Aug 5, 2026, 3:06 PM AEST
Bio-Gene Technology Market Cap
Bio-Gene Technology has a market cap or net worth of 8.88 million as of August 5, 2026. Its market cap has increased by 53.20% in one year.
Market Cap
8.88M
Enterprise Value
7.80M
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
0.02
ChartMarket Cap Chart
Since November 29, 2017, Bio-Gene Technology's market cap has decreased from 20.89M to 8.88M, a decrease of -57.50%. That is a compound annual growth rate of -9.38%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 5, 2026 | 8.88M | 26.56% |
| Dec 29, 2025 | 7.02M | -18.97% |
| Dec 30, 2024 | 8.66M | -28.33% |
| Dec 29, 2023 | 12.08M | -32.09% |
| Dec 29, 2022 | 17.79M | -48.81% |
| Dec 31, 2021 | 34.76M | 61.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Nov 29, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ceryvyn Therapeutics | 15.05M |
| ReNerve | 14.65M |
| Immuron | 11.76M |
| AdAlta | 11.24M |
| Cambium Bio | 11.21M |
| Invex Therapeutics | 8.27M |
| Vectus Biosystems | 7.99M |
| Zelira Therapeutics | 5.95M |